<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00966368</url>
  </required_header>
  <id_info>
    <org_study_id>NN1250-1988</org_study_id>
    <secondary_id>U1111-1122-2992</secondary_id>
    <secondary_id>2011-002949-35</secondary_id>
    <secondary_id>P/44/2010</secondary_id>
    <secondary_id>P/96/2011</secondary_id>
    <nct_id>NCT00966368</nct_id>
  </id_info>
  <brief_title>Comparison of Two NN1250 Formulations in Healthy Volunteers</brief_title>
  <official_title>A Trial to Test for Bioequivalence Between Two NN1250 Formulations in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial was conducted in North America. The aim of this clinical trial was to investigate
      if two formulations of NN1250 (insulin degludec) have the same level of drug exposure to the
      body.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the Insulin Degludec concentration-time curve from 0 to 120 hours after single dose</measure>
    <time_frame>From 0 to 120 hours after dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed Insulin Degludec concentration after single dose</measure>
    <time_frame>From 0 to 120 hours after dosing</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to maximum observed Insulin Degludec concentration after single dose</measure>
    <time_frame>From 0 to 120 hours after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the Insulin Degludec concentration-time curve from 0 to 24 hours after single dose</measure>
    <time_frame>From 0-24 hours after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life for Insulin Degludec</measure>
    <time_frame>From 0 to 120 hours after dosing</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Diabetes</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>IDeg E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>IDeg M</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin degludec</intervention_name>
    <description>Single dose of NN1250, formulation 1, 0.4U/kg body weight injected subcutaneously (under the skin)</description>
    <arm_group_label>IDeg E</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin degludec</intervention_name>
    <description>Single dose of NN1250, formulation 2, 0.4U/kg body weight injected subcutaneously (under the skin)</description>
    <arm_group_label>IDeg M</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Considered generally healthy upon completion of medical history, physical examination,
             vital signs and ECG (electrocardiogram), as judged by the Investigator

          -  Body mass index 18.0-27.0 kg/m^2 (both inclusive)

        Exclusion Criteria:

          -  Subject who has donated any blood or plasma in the past month or more than 500 mL
             within 3 months prior to screening

          -  Smoker (defined as a subject who is smoking more than 5 cigarettes or the equivalent
             per day)

          -  Not able or willing to refrain from smoking and use of nicotine gum or transdermal
             nicotine patches during the inpatient period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91911-1350</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2009</study_first_submitted>
  <study_first_submitted_qc>August 25, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2009</study_first_posted>
  <last_update_submitted>September 24, 2015</last_update_submitted>
  <last_update_submitted_qc>September 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Long-Acting</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

